ArticleBMC cardiovascular disorders2025
Efficacy and safety of emergent balloon aortic valvuloplasty as a rescue therapy for cardiogenic shock due to severe aortic stenosis in non-TAVI centers.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of aortic stenosis (AS) with cardiogenic shock remains poor, and optimal initial treatment remains unclear. Emergent balloon aortic valvuloplasty (BAV) is a treatment option for salvage and recent studies have reported that early release of valve obstruction by emergent BAV could improve prognosis. This study aimed to assess the efficacy and safety of emergent BAV for severe AS with cardiogenic shock.
methodsAmong 8,230 patients hospitalized for heart failure, 7924 patients with heart failure unrelated to severe AS were excluded. Among the remaining 306 patients, 256 patients who developed cardiogenic shock due to other causes except severe AS were further excluded. Finally, a total of 41 patients with severe AS in cardiogenic shock were enrolled and divided into the emergent (underwent BAV within 6 h of admission, n = 9) and non-emergent (underwent BAV more than 6 h after admission, n = 16) groups, after excluding 16 patients who did not undergo BAV. The primary endpoints were the 30-day mortality rate and procedural complications. The secondary endpoints were days to withdrawal from the mechanical support device, days to initial rehabilitation, and clinical frailty scale (CFS) score at discharge.
resultsIn the emergent group, the time from admission to BAV was 3.0 ± 1.4 h, whereas BAV was performed 4.5 days (median) after admission in the non-emergent group. The 30-day mortality rate was not significantly different between the emergent and non-emergent groups (0% vs. 25%, p = 0.260); furthermore, there was no statistically significant difference regarding the incidence of procedural complications (0% in the emergent vs. 12.5% in the non-emergent group, p = 0.520). The days to withdrawal from mechanical support device and to start rehabilitation were earlier in emergent group (2.9 ± 1.2 days vs. 7.8 ± 4.6 days; p = 0.008, 4.2 ± 1.9 days vs. 10.8 ± 6.5 days; p = 0.004). The CFS score at discharge in the emergent group was maintained compared to before admission (from 3.8 ± 1.0 to 3.9 ± 1.1; p = 0.347), whereas worsened in the non-emergent group (from 3.8 ± 0.9 to 4.6 ± 1.2; p = 0.032).
conclusionsEmergent BAV for cardiogenic shock is feasible, and earlier BAV may support faster recovery and help prevent deterioration of frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.